A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

Panuveitis Clinical Trial

— LUMINATE  

Official title:

A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00404885
• Other study ID #: LX211-03-UV
• Secondary ID: EudraCT No: 2006
• Status: Completed
• Phase: Phase 3
• First received: November 27, 2006
• Last updated: June 21, 2012
• Start date: January 2007
• Est. completion date: May 2009

Study information

• Verified date: June 2012
• Source: Lux Biosciences, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis

Recruitment information / eligibility

• Status: Completed
• Enrollment: 108
• Est. completion date: May 2009
• Est. primary completion date: November 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 13 Years and older

Eligibility

Inclusion Criteria:

• Documented history of non-infectious anterior, anterior and intermediate- or panuveitis

• Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy due to the development of an ocular hypertensive response or subjects for whom oral corticosteroid is contraindicated.

• Grade of 2+ or higher for anterior chamber cells at time of enrollment

• Considered by the investigator to require corticosteroid-sparing therapy.

• Subjects not planning to undergo elective ocular surgery during the study

Exclusion Criteria:

• Uveitis of infectious etiology

• Presence of an ocular toxoplasmosis scar

• An immune suppression regimen that includes an alkylating agent within the previous 90 days

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Iridocyclitis
• Iritis
• Panuveitis
• Uveitis
• Uveitis, Anterior

Intervention

Drug:
• Placebo
PO BID
• LX211
0.2 mg/kg, twice a day (BID)
• LX211
0.4 mg/kg, twice a day (BID)
• LX211
0.6 mg/kg, twice a day (BID)

Locations

Country	Name	City	State
Austria	Universitätsklinik für Augenheilkunde	Salzburg
Austria	Klinik für Augenheilkunde, Dept. of Ophthalmology	Wien
Canada	McGill University Health Center	Montreal	Quebec
France	Hôpital Pitié Salpétrière, Service d'Ophtalmologie	Paris
Germany	Universitätsklinikum Freiburg	Freiburg
Germany	Augenklinik der Universität Heidelberg	Heidelberg
Germany	St. Franziskus-Hospital	Münster
Germany	Universitätsklinikum Tübingen	Tübingen
India	Vittala International Institute of Ophthalmology	Bangalore
India	Advanced Eye Centre, Postgraduate Institute of Medical Education and Research (PGIMER)	Chandigarh
India	Aravind Eye Hospital, Uvea Clinic	Coimbatore
India	L V Prasad Eye Institute	Hyderabaad	Andhra Pradesh
India	Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology	Madurai	Tamil Nadu
India	Aditya Jyot Eye Hospital Pvt Ltd	Mumbai
United Kingdom	Bristol Eye Hospital and University of Bristol	Bristol
United Kingdom	Royal Liverpool University Hospital	Liverpool
United States	Brian B. Berger, MD, P.A.	Austin	Texas
United States	Wilmer Eye Institute	Baltimore	Maryland
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Massachusetts Eye and Ear Infirmary	Boston	Massachusetts
United States	Massachusetts Eye Research and Surgery Institute	Cambridge	Massachusetts
United States	University of Illinois - Chicago	Chicago	Illinois
United States	Duke University Eye Center, Erwin Road	Durham	North Carolina
United States	Associated Retinal Consultants, PC	Grand Rapids	Michigan
United States	Tauber Eye Center	Kansas City	Missouri
United States	New York Eye & Ear Hospital	New York	New York
United States	Viginia Eye Consultants	Norfolk	Virginia
United States	Retinal Consultants of Arizona	Phoenix	Arizona
United States	Oregon Health Sciences University	Portland	Oregon
United States	Retina & Uveitis Consultants of Texas	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Lux Biosciences, Inc.

Countries where clinical trial is conducted

United States,  Austria,  Canada,  France,  Germany,  India,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	anterior chamber cells		16 and 24 weeks	No
Secondary	BCVA		24 weeks	No
Secondary	macular thickness		16 and 24 weeks	No

External Links

•   Link